2017 Speaking Faculty

In her role, Cheryl leads Diplomat’s Industry Relations team in finding partnerships and crafting health care solutions. Specifically, Cheryl leads Diplomat’s corporate efforts in identifying new opportunities within the pharmaceutical industry. She then collaborates with manufacturers to design services and distribution solutions that support their patients’ journey

Cheryl brings more than 25 years of industry experience, with work in independent and specialty pharmacy, as well as in managed care consulting and health care IT. Before joining Diplomat in July 2011, Cheryl worked as the senior director of clinical services at Sanovia Corporation, where she managed new product development and sales support. Prior to her tenure at Sanovia, she held roles with Priority HealthCare as a pharmacist-in-charge for oncology and lead pharmacist for pain management. Cheryl also founded C. Allen & Associates, a firm focused on managed care consulting, and Eden Drug Company, an independent pharmacy.

Cheryl earned her Bachelor of Science in pharmacy at Samford University’s McWhorter School of Pharmacy, and her MBA at Saint Joseph’s University Erivan K. Haub School of Business with a focus in pharmaceutical and health care marketing.

Sheila Arquette is a 1989 magna cum laude graduate of the State University of New York at Buffalo School of Pharmacy. Sheila has been employed at Independent Health for over 11 years, assuming the Director of Pharmacy Services in July 2014. She has extensive experience in retail and hospital pharmacy practice in addition to the managed care, PBM and specialty pharmacy space.

Prior to joining Independent Health I worked in almost every pharmacy practice setting. I have practiced as a community pharmacist in the capacity of staff pharmacist at large chain stores and as the supervising pharmacist for a supermarket chain and as a relief pharmacist for a local independent pharmacy; as a clinical pharmacist for several hospitals across New York State; as a staff pharmacist in long term care pharmacy as well as the LTC pharmacy consulting space.

In 2003 I joined Independent Health as a clinical review pharmacist in the prior authorization department. I was then promoted to the prior authorization department manager and then again to the assistant director of pharmacy for all clinical services. In my current role I am responsible for the oversight of the pharmacy prior authorization department, clinical decision accuracy and reliability, the timeliness of our decisions, regulatory compliance with all CMS, NCQA and DOH requirements, medical director education and support, drafting and maintaining all pharmacy drug specific and administrative policies, formulary design and the oversight of the ongoing maintenance of 10 drug formularies for the following lines of business: commercial, Medicare advantage, managed Medicaid, exchange and employer group self-funded pharmacy benefit designs. I am actively involved with Medicare compliance as it relates to both clinical policies and procedures and PBM related functions. I am directly responsible for all specialty pharmacy operations including medical and pharmacy benefit drug channel management, drug access, contracting, service metrics, reporting and the quantification of intervention related health outcomes. In 2010 Independent Health opened our own specialty pharmacy-RelianceRx. I was integrally involved in the implementation of RelianceRx since its inception and continue to oversee all operations and patient/provider services from the health plan perspective. I work closely with the specialty pharmacy management staff to ensure our collective strategic objectives are met. Independent Health is also its own PBM and I am responsible for providing the clinical support required for our PBM to effectively administer our formulary management edits and benefit designs. Independent Health offers a self- funded pharmacy benefit and self- funded medical TPA services. I serve as the clinical support to our self-funded benefit account management teams and employer group representatives. I am responsible for the network participating pharmacy audit process including all audit related functions and recovery. I manage our pharmacy network MAC list and serve as the clinical liaison to other departments of the health plan including medical resource management, special case review, benefit administration, and medical director staff. I am a non-voting member of our Pharmacy and Therapeutics Committee and clinical appeals team member. I am the pharmacy clinical representative for all adverse determination appeal related administrative matters and legal proceedings with Maximus and Medicare administrative law judge case review. I also provide the pharmacy clinical support for all managed Medicaid fair hearing proceedings. I am also responsible for providing 24/7 on-call pharmacy support to our members, providers and pharmacies. I currently have 5 direct reports and 20 indirect reports.

I am a current member of AMCP and NASP.

Eric Baim is the Vice President and Head of U.S. Compliance at Shire based in Lexington, MA. As a senior governance, risk and compliance executive, Eric has over 15 years of experience successfully leading, enabling and integrating governance, risk management, integrity and compliance responsibilities for pharmaceutical, medical device, biotech and other healthcare organizations. In this capacity, he has supported the growth and transformation of a number of patient services functions. Prior to joining Shire, Eric has various compliance roles at Novartis in New Jersey and, before that, practiced as an attorney in Washington, DC. Eric has law and public policy degrees from Duke University and a Masters in Psychology from the University of Cincinnati. He did is undergraduate work at the University of North Carolina at Chapel Hill.

Derek Cothran, Vice President and Lead, Strategic Account Management, partners closely with manufacturers to create a comprehensive access strategy as well as facilitate the evolution of this strategy throughout the product or program lifecycle. Derek proactively incorporates market trends and industry capabilities to help manufacturers create a service offering to meet patient and provider needs.

In his previous role as VP of Operations, Derek provided strategic direction to multiple clients for their specialty medications across a range of disease states and provided direct operational oversight into manufacturer programs. He continues to work closely with other AmerisourceBergen companies to integrate appropriate service needs such as clinical adherence, specialty distribution and strategic consulting.

Mahnu Davar is a Partner in the Lifesciences Regulatory Practice at Arnold & Porter Kaye Scholer in Washington, DC. His practices focuses on counseling pharmaceutical, biotechnology, and medical device companies on complex regulatory and compliance issues – particularly in the R&D;, marketing and product support, grants and charitable giving, and manufacturing areas. He has led numerous internal investigations and compliance audits, assisted companies to develop their US and global compliance programs, and defended companies in healthcare fraud enforcement actions.

Adam J. Fein, Ph.D., is the president of Pembroke Consulting, Inc., a management advisory and business research firm based in Philadelphia. He also is the CEO of Pembroke’s Drug Channels Institute, a leading management educator for and about the pharmaceutical industry.

Dr. Fein is one of the country’s foremost experts on pharmaceutical economics and the drug distribution system. Top manufacturers call on Dr. Fein’s insights and judgment to create successful commercial strategies and make better strategic decisions in our evolving healthcare environment.

Dr. Fein’s popular and influential Drug Channels website (DrugChannels.net) is the go-to source for definitive and comprehensive industry analysis, delivered with a witty edge. He has published hundreds of academic and industry articles, and is regularly quoted in such national publications as The Wall Street Journal, The New York Times, Fortune, Drug Benefit News, and many others.

Dr. Fein earned his doctoral degree from the Wharton School of Business at the University of Pennsylvania and a B.A., summa cum laude, from Brandeis University. He lives in Philadelphia with his wife and their two children.

Patricia J. Goldsmith joined CancerCare in 2014 as Chief Executive Officer, overseeing the vision and direction of the organization. Ms. Goldsmith brings more than 20 years of nonprofit management and strategic planning experience to the role, and has a proven track record of success in hospital and physician academic organizations, as well as nongovernmental health care organizations.

She previously served as Executive Vice President and Chief Operating Officer at the National Comprehensive Cancer Network (NCCN). In this role, Ms. Goldsmith was responsible for the overall operations of NCCN. She reported directly to the Chief Executive Officer and provided oversight of the functions of NCCN Oncology Outcomes Database, NCCN Oncology Research Program, Finance, U.S. & Global Business Development, Marketing and Communications, Public Affairs, Professional Publications, Best Practices, Analytics, Research & Consulting, Conferences and Meeting Planning, Media Programs, Continuing Medical Education and Grants and Information Technology. In addition, she was responsible for public policy initiatives at the Federal level and national initiatives related to payors and employers including the education related to these constituencies. Ms. Goldsmith was also responsible for the NCCN Foundation, established as the philanthropic affiliate of NCCN to embrace the NCCN mission of improving the quality and effectiveness of care provided to patients with cancer. Ms. Goldsmith formerly served as Vice President for Institutional Development, Public Affairs and Marketing at the Moffitt Cancer Center in Tampa, Florida – an NCCN Member Institution. There she oversaw the Moffitt Cancer Center's Foundation, Public Relations, Marketing, and Business Development functions in addition to fundraising initiatives. Before joining Moffitt, she developed and directed all managed care activities for the University of South Florida College of Medicine.

A frequent speaker at national meetings and symposia, Ms. Goldsmith was chosen by U.S. Representative Bill McCollum (R-Fl.) in 2003 to join a panel of 100 thought leaders representing every stakeholder interest in health care. This unique effort focused on building consensus about what structural changes could be made in our nation's health care delivery system to assure quality health care for future generations. Recently, Ms. Goldsmith participated as a faculty panel member at Bristol-Myers Squibb’s 2015 Market Access Summit focusing on the patient experience from diagnosis, through treatment, and beyond, and at the Fifth Annual Association for Value Based Cancer Care (AVBCC) Conference where her session focused on patient engagement and patient assistance. Prior to these conferences, Ms. Goldsmith participated as a speaker at the 16th Annual Patient Assistance & Access Programs (PAP) Meeting, her session entitled, “Cross-Functional Strategies for Advocacy Relationship Development,” and as a panel participant at the Turning the Tide Against Cancer Through Sustained Medical Innovation Conference, her session entitled, “Addressing the Value and Cost of Cancer Care.”

Ms. Goldsmith has studied at the Pennsylvania State University, the University of Missouri Bloch School of Business and the Harvard School of Public Health. She was a winner of the 1999 Distinguished Women in Business Award sponsored by the Business Journal of Tampa Bay and also was named the 1999 Leukemia Society Woman of the Year, an award based on her philanthropic efforts on behalf of the Leukemia Society.

Paul Ham is Executive Director of Corporate Compliance at Bioverativ, a recent spin-off from Biogen focusing on rare blood disorders. Prior to Bioverativ, he held compliance roles at Biogen and at Sunovion. Before entering the industry, he was an attorney at DLA Piper in Boston, where he focused on pharmaceutical compliance investigations. He has an undergraduate degree from Williams College, a master’s degree in policy from Harvard University, and his law degree from Boston College.

Laura Hoey is a partner in the government enforcement practice at Ropes & Gray LLP in Chicago. Laura combines her trial and investigative skills as a former federal health care fraud prosecutor with extensive experience in the health care industry. Laura is known for creative and tenacious defenses and for efficient, well-managed internal investigations. She represents clients in the pharmaceutical, medical device, diagnostic laboratory, and dental industries who are facing government investigations and Congressional inquiries. Laura conducts internal investigations in all types of government and regulatory compliance matters including:

• potential violations of whistleblower and anti-kickback statutes and of anti-corruption and anti-bribery statutes, including the U.S. Foreign Corrupt Practices Act,
• alleged health care fraud,
• alleged improper marketing of pharmaceutical products and medical devices for uses for which they have not been approved by the FDA (off-label marketing), and
• alleged violations of privacy and data security laws, including HIPAA.

As a federal prosecutor, Laura prosecuted health care fraud, kickback violations, Food, Drug and Cosmetic Act violations, document destruction and obstruction cases, and criminal HIPAA violations, as well as tax fraud and public corruption. She was first chair in five trials, winning convictions in all five. In 2008, Laura received the Department of Health and Human Services Office of the Inspector General’s Integrity Award.

Laura is a member of the firm’s Privacy Working Group, the Co-Chair of the Firm's Women's Forum, and a Member of the Pro Bono Committee.

Tom Hubbard leads NEHI’s projects on comparative effectiveness research, patient medication adherence, and prevention and wellness initiatives. Mr. Hubbard leverages his policy and technology experience to examine ways the country’s health care system can be transformed, focusing on the promotion of medical innovation and the improvement of quality and efficiency in clinical care.

Mr. Hubbard came to NEHI after seven years at the Massachusetts Technology Collaborative (MTC), where he led industry-focused projects and supervised the annual publication of the MTC Index of the Massachusetts Innovation Economy. His work has included supervising the I-495 Technology Corridor Partnership, an industry-municipal collaboration on growth, and leading projects on broadband deployment, federal research funding advocacy, and nanotechnology.

Previously, Mr. Hubbard served as Executive Assistant for Economic Affairs to U.S. Senator John Kerry, as Deputy Director of Development for Massachusetts Governor Michael Dukakis, and as Director of Community Development and Planning for the City of Gardner, Massachusetts.

Mr. Hubbard graduated from Harvard College and holds a masters in public policy from Harvard’s Kennedy School of Government.

Marci is a seasoned management consultant with over 13 years of pharmaceutical experience. She specializes in advising life science companies on optimizing operational processes while addressing compliance. Areas she focuses on include aggregate spend/disclosure, patient services support, sales and marketing, medical affairs, and clinical trials. Her extensive experience includes providing pharmaceutical, medical device and biotechnology companies with effective advice on program implementation, operational excellence, change management, data analytics, compliance adherence, and risk mitigation. Prior to Helio, Marci was a Director at Huron Consulting Group’s Life Sciences Practice. Marci began her career in Ernst & Young’s Fraud, Investigation and Dispute Services group focusing on healthcare challenges.

John Kelly joined Bass, Berry & Sims in January 2012 and is Managing Partner of the firm’s Washington D.C. office. He has extensive experience with complex federal and state investigations and litigation in matters related to healthcare fraud and abuse, the False Claims Act, white collar crime, the Foreign Corrupt Practices Act, and regulatory and compliance issues. He also has experience in matters involving allegations of insurance fraud, securities and accounting fraud, mail and wire fraud, bank fraud, and money laundering. John’s practice spans across a number of industries with a particular emphasis on healthcare and life sciences.

John began his career as a federal prosecutor with the Department of Justice where he held a number of leadership positions, including serving in the Criminal Division’s Fraud Section as the Assistant Chief for Health Care Fraud. In that role, John focused on investigating and prosecuting healthcare fraud matters nationwide. During his service in the Health Care Fraud section, John was selected to direct the Department of Justice’s Medicare Fraud Strike Force in Los Angeles, California. His experience in healthcare fraud cases covers a range of trials and investigations involving violations of the Anti-Kickback Statute, the False Claims Act, and anti-money laundering prohibitions. He also served as the Chief of Staff and Deputy Director of the Executive Office for U.S. Attorneys, where he worked closely with senior leadership within the 94 U.S. Attorneys' Offices, the Department of Justice, and various federal agencies including HHS-OIG, FBI, and DEA. Prior to joining DOJ, John gained extensive trial experience as an Assistant United States Attorney in New York State.

John is a frequent speaker and writer on topics related to healthcare fraud and abuse, compliance programs, and the FCPA. He has been invited to speak at conferences and seminars nationwide. In addition, John was a regular instructor at the Department of Justice’s national training center lecturing on trial advocacy, criminal procedure, demonstrative evidence, ethics, and healthcare fraud. He was selected by the Justice Department to teach trial advocacy and criminal procedure to judges and prosecutors in Armenia and Azerbaijan.

Publications
Co-author, "Smith & Nephew's $22 Million Settlement Highlights Medical Device Industry's FCPA Risk," AHLA Fraud & Abuse Email Alert, February 13, 2012
Co-author, "The FCPA's Increasingly Global Reach," Law360 Competition, May 19, 2011
Co-author, "Safely Navigating the Surge of M&A; Activity: Pre-Acquisition Corruption Due Diligence," ILO Newsletter, Globe Business Publishing Ltd., January 24, 2011
Co-author, "The Effect of Sentencing Guidelines Amendments," Law360, December 2010
Co-author, "Amendments to Organizational Sentencing Guidelines Take Effect," ILO Newsletter, Globe Business Publishing Ltd., November 15, 2010
Co-author, "Foreign Corrupt Practices Act Pharmaceutical investigation Expands," ILO Newsletter, Globe Business Publishing Ltd., August 31, 2010
Co-author, "DOJ Issues Guidance on Government-Compelled Grants," ILO Newsletter, Globe Business Publishing Ltd., August 16, 2010
Co-author, "French Issuer Pays $338 Million in Fines and Disgorgement for FCPA Violations," ILO Newsletter, Globe Business Publishing Ltd., July 26, 2010
Co-author, "The Foreign Corrupt Practices Act The Healthcare Industry is Under the Microscope," AHLA's Practice Group Report: International Healthcare Update, April 13, 2010
Co-author, "Guilty Plea Highlights Increased FCPA Enforcement in 2010," ILO Newsletter, Globe Business Publishing Ltd., April 6, 2010
Co-author, "FCPA Enforcement Update. DOJ Targets Health Care Companies," National Association of Criminal Defense Lawyers, The Champion Magazine, March 2010
Co-author, "Interim Final Rule Creates New Penalties for HIPAA Violations," HCCA Compliance Today, Volume 12, No. 3, March 2010
Co-author, "Foreign Corrupt Practices Act Enforcement: DOJ Targets Healthcare Industry," ILO Newsletter, Globe Business Publishing Ltd„ February 1, 2010
Co-author, "Largest Single Action Against Individuals in Foreign Corrupt Practices Act History," ILO Newsletter, Globe Business Publishing Ltd., February 1, 2010
Co-author, "Fines for UTStarcom for Violating Corrupt Practices Act," ILO Newsletter, Globe Business Publishing Ltd., January 25, 2010
Co-author "The Impact of Law Enforcement Trends and Legislative Reform on the Health Care Industry," BNA's Health Care Fraud Report, Vol. 13., No. 24, P. 971-74, December 16, 2009
Co-author, "Former U.S. Representative William Jefferson Sentenced to 13 Years' Imprisonment," ILO Newsletter, Globe Business Publishing Ltd., December 7, 2009
Co-author, "Pharmaceutical Companies Receive Foreign Corrupt Practices Act Warning," ILO Newsletter, Globe Business Publishing Ltd., November 2009
Co-author, "Importance of Effective Anti-corruption Programmes," ILO Newsletter, Globe Business Publishing Ltd., November 9, 2009

"Physician Owned Distributorships," ABA Health Law Section's Conference on Emerging Issues in Healthcare Law, February 24, 2012
Co-panelist, "What’s Ahead for 2012: The OIG Work Plan and Health Care Enforcement Trends," DC Bar Association event, February 22, 2012
"Off-Label Promotion: Recent Enforcement Actions," Q1 Productions Medical Device Regulatory Clearance & Approval Conference, December 9, 2011
Co-presenter, "Hot Topics in Healthcare: Privacy, Antritrust and Fraud," Webinar, December 2011
"Corporate and Individual Risk Mitigation when Responding to a Government Inquiry/Investigation," CBI 13th Annual Guidelines for Disseminating Off-Label Information, October 17, 2011
Co-presenter, "A Primer on Foreign Corrupt Practices Act and Anti-Corruption Issues for Healthcare and Life Science Companies, Part III: Defensive Strategies in Conducting an FCPA Compliance Investigation and Responding to a Government Inquiry," American Health Lawyers Association webinar, July 14, 2011
Co-presenter, "Legislative Hot Topics," Compliance in Action: Ethics and Compliance Issues for In-House Counsel in the Energy Sector, Houston, TX, June 9, 2011
Co-presenter, "Compliance Investigations," and "Stark, Anti-Kickback and False Claims Act Basics," Legal Issues Boot Camp for Compliance Professionals, Houston, TX, June 7-8, 2011
Co-panelist, "A Primer on Foreign Corrupt Practices Act and Anti-Corruption Issues for Healthcare and Life Science Companies, Part II: Establishing Compliance Controls to Minimize FCPA and Anti-Corruption Risks for Healthcare and Life Science Companies," American Health Lawyers Association webinar, June 1, 2011
Co-panelist, "A Primer on Foreign Corrupt Practices Act and Anti-Corruption Issues for Healthcare and Life Science Companies, Part I: FCPA and Anti-Corruption 101 for Healthcare and Life Science Companies," American Health Lawyers Association webinar, May 11, 2011
Co-panelist, "FCPA: Critical Issues and Best Practices for Life Sciences Companies," Web Seminar, April 14, 2011
"Fraud and Abuse Enforcement Trends in Health Care," Health Law Symposium, Houston, TX, February 2011
Co-panelist, "Minimizing FCPA Risk when Conducting Clinical Trials Abroad at State-Run Hospitals and Trial Sites," Managing Legal and Regulatory Risks in Structuring and Conducting Clinical Trials, American Conference Institute, Philadelphia, PA, January 2011
Co-panelist, "Overcoming Legal Obstacles to Implementation," National Forum on Clinical Integration, American Conference Institute, Washington, DC, November 2010
Co-panelist, "Developing a Critical Action Plan," Government Investigations for Life Sciences, American Conference Institute, Philadelphia, PA, September 2010
Co-panelist, "Spotlight on Enforcement: New Trends Triggering Off-Label Investigations," American Conference Institute, Philadelphia, PA, July 2010
Co-panelist, "Preparing for Shifting FCPA Enforcement Trends and New Government Investigation Techniques in the Life Sciences Industry," American Conference Institute, New York, NY, May 2010
Co-panelist, "Health Care Reform Fraud and Abuse and Enforcement Initiatives," national web seminar, April 2010
Co-panelist, "Insights on Recent Government Investigative and Enforcement Initiatives in the Medical Device Industry," American Conference Institute, Chicago, IL, April 2010
Co-panelist, "Conducting an Internal Investigation and Effectively Responding to the Government," American Conference Institute, New York, NY, March 2010
Co-panelist, "FCPA: The Critical Issues Facing the Medical Device and Pharmaceutical Industries," KPMG ShareForum, Washington, DC, March 2010
"The Foreign Corrupt Practices Act in the Health Care Industry," audio conference, Health Ethics Trust, Washington, DC, March 2010
"Healthcare Reform and Enforcement and its Impact on Compliance," Best Compliance Practices Forum, Health Ethics Trust, October 2009
Co-presenter, "2009 Health Law Educational Program: The Government Strikes: Responding to Searches and Investigations," national web seminar, September 2009
Co-presenter, "Crisis Management in the Healthcare Setting: A Case Study,' national web seminar, September 2009
"Fraud and Abuse the Sale and Marketing of Drugs," American Conference Institute, New York, NY, April 2009
"FCPA Compliance: What You Don't Know Can Hurt You," AdvaMed Conference, national web seminar, April 2009
"Fraud and Compliance in the Hospital / Physician Setting," Health Care Financial Management Association, Dallas, TX, January 2009
Co-panelist, "Enforcement and Compliance Roundtable," American Bar Association's Washington Health Care Summit, Washington, DC, November 2008
"Selecting a Jury in Health Care Fraud Trials," National Advocacy Center, Columbia, South Carolina, March 2008
Co-panelist, "Managing Legal Risks in Clinical Trials," American Conference Institute, New York, New York, February 2008
"Legal Issues in Health Care Fraud," National Health Care Anti-Fraud Association, Chicago, Illinois, July 2007
Outside of work, John enjoys playing basketball, scuba diving, reading, and spending time with his family.

Kesslyn Smith is an experienced leader in the building of innovative, patient-centric reimbursement and patient support programs. She has served patients across a broad range of disease states at Sanofi and its predecessor companies, at Otsuka, and more recently at Sandoz Biopharmaceuticals where she designed, developed and launched a comprehensive reimbursement support program for the first Biosimilar product in the U.S.

Kesslyn initially made her mark in Oncology where she was responsible for strategic oversight and management of initiatives in oncology patient assistance, national patient advocacy programs, and support programs for the underinsured, including co-pay assistance. She has also held positions in oncology clinical operations and global marketing.

Kesslyn is a respected and admired advocate in the patient access community, where she has served on several strategic advisory committees. In addition, she has chaired large industry events and is a key industry speaker on topics such as healthcare reform, affordability, specialty distribution and an array of other topics related to supporting patients’ needs.

Kesslyn also is the recipient of several industry awards including Patient Advocate Foundation’s “Humanitarian Advocacy Award”, and in 2013 she was the inaugural recipient of AmerisourceBergen “Commitment to Patient Care” Award, honoring one individual who has spent their career advocating for patient access and outcomes and has been able to achieve results.

Manny has 19 years of pharmaceutical industry and management consulting experience, specializing in predictive modeling and advanced analytics, sales force effectiveness, multi-channel marketing, aggregate spend/disclosure strategy and analysis and information technology. Prior to founding Helio, Manny was a Managing Director at Huron Consulting Group where he was a senior partner in the life sciences practice. Before joining Huron, Manny was a Client Partner in the life sciences practice for Fair Isaac Corporation (FICO), where he was the expert on pharmaceutical data management and multi-channel marketing best practices. Prior to Fair Isaac Corporation, Manny created and managed the Professional Services Group (PSG) at Dendrite International as Managing Director, and was also a senior executive with Accenture’s Pharmaceutical & Medical Products Customer Relationship Management (CRM) division. Manny began his career in sales, sales operations and business analysis at Novartis Pharmaceuticals / Ciba Geigy.

Joel Wright was named President and Chief Executive Officer of a combined specialty and mail services company with AllianceRx Walgreens Prime that launched on April of 2017. This combined company is a subsidiary of Walgreens, the Retail Pharmacy USA Division of Walgreens Boots Alliance, and will be headquartered in Chicago, Ill.

Mr. Wright previously was Divisional Vice President of Walgreens Specialty Solutions Group, a division dedicated to providing patients with complete specialized pharmaceutical care to treat chronic, rare or complex conditions. During his tenure from 2013 - 2016, Mr. Wright developed and executed a successful go-to-market strategy for five central specialty and 250 local specialty pharmacies throughout the U.S. and Puerto Rico. Under his leadership, the Specialty Solutions Group nearly doubled its sales and amassed more than $8 million in annual revenue.

Before leading the specialty division, Mr. Wright held a variety of leadership roles of increasing responsibility at Walgreens. He began his Walgreens career 22 years ago as a Pharmacy Manager and Supervisor and has since served as Vice President of Home Care, Executive Director of Pharmacy and Senior Director of Healthy System Operations.

Mr. Wright holds a Bachelor of Pharmacy degree from the Ferris State University in Grand Rapids, MI. He also completed the Executive Management Program for Pharmacy Leaders at University of Pennsylvania’s Wharton School of Business.